India Glycols Limited — Investor Meet, 20-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

India Glycols reported a strong Q1 FY27: Net Revenue at ₹1,130 Cr (+9%), EBITDA at ₹170 Cr (+13%), and PAT up 32%. Finance costs significantly reduced due to debt reduction. NCLT approval for business restructuring has been received.

**Segment Performance:** IGL Spirits (Spirits + Bio-Fuel) posted ₹694 Cr Net Revenue and ₹120 Cr EBITDA (+17%), with IMFL revenue up 26% and cases jumping 55% to 1.4 million. India Glycols (Chemicals) saw 25% revenue growth to ₹345 Cr. Ennature Bio Pharma achieved its best-ever quarter, revenue up 53% to ₹90 Cr, EBITDA up 100% to ₹10 Cr, driven by nutraceutical launches and nicotine expansion.

**Future Outlook:** Management is confident in strategic growth. Spirits targets over ₹500 Cr EBITDA for FY27, aiming for debt-free by FY28 and over ₹1,000 Cr EBITDA in 4-5 years via premiumization and strategic partnerships (like Amrut). Chemicals aims for ₹400 Cr EBITDA and ₹2,500 Cr revenue, powered by bio-based innovation. Bio Pharma seeks ₹130-150 Cr EBITDA in 4-5 years, focusing on its branded portfolio and global reach. Management expressed positivity on sustained margin improvement.